Acoustica offers a proprietary acoustophoretic platform that concentrates biologic drugs into ultra‑high‑concentration microgel suspensions (>500 mg/mL) while maintaining low viscosity and stability. This enables pharmaceutical companies to reformulate monoclonal antibodies and other large‑molecule therapeutics for small‑volume subcutaneous injections that can be administered at home, reducing reliance on hospital‑based IV infusions.
Funding
Funding not disclosed
Founders
Product
Problem
Many monoclonal antibody therapies require high‑dose intravenous infusions in clinical settings because formulating them at the concentrations needed for subcutaneous injection makes the solutions overly viscous and unstable. This limits patient convenience, increases healthcare costs, and restricts the use of biologics outside hospitals.
Solution
Acoustica provides a proprietary acoustophoretic platform that creates ultra‑high‑concentration microgel suspensions of biologics, achieving concentrations above 500 mg/mL while maintaining low viscosity and stability. By gently handling the proteins, the technology enables formulation of monoclonal antibodies and other large molecules into small‑volume subcutaneous injections that can be administered at home. The platform is compatible with a wide range of biologic materials and integrates into existing manufacturing workflows with minimal product loss. This converts hospital‑based IV therapies into patient‑friendly injection formats, expanding access and reducing administration costs.
Target Audience
Primary customers are pharmaceutical companies and biologics developers seeking to reformulate existing or pipeline monoclonal antibody products for subcutaneous delivery.
Features
- Acoustophoretic processing that concentrates biologics to >500 mg/mL without compromising stability
- Microgel suspension formulation delivering low‑viscosity, high‑concentration solutions suitable for subcutaneous injection
- Gentle, low‑shear handling preserving protein integrity and minimizing product loss
- Broad material compatibility covering diverse monoclonal antibodies and biologic modalities
- Scalable process that can be incorporated into existing biomanufacturing pipelines